Introduction
Recent progress in molecular genetics has greatly improved our understanding of the molecular basis of many inherited neurologic diseases. The chromosomal position of a large number of genes which, when mutated, can cause neurologic disorders, is now known. In many cases the genes themselves and their disease causing mutations have been identi®ed. This increasing wealth of knowledge has allowed the reclassi®cation of a number of formerly heterogeneous clinical syndromes, provides novel diagnostic possibilities, and allows characterization of the pathologic gene products, thereby providing further insight into the molecular pathogenesis of these disorders and eventually opening up new approaches towards therapy and prevention. Today and in the years to come, the rapid advances in neurogenetics will be a challenge to neurologists everywhere.
In clinical practice, the availability and the limitations of molecular diagnosis depend on our knowledge of the molecular genetic basis of the respective disease, but also on the degree of genetic complexity of the disorder under investigation. Some diseases, such as Huntington's disease, are caused by a speci®c mutation in a single gene (Huntington's Disease Collaborative Research Group, 1993) , and routine molecular diagnosis can be provided by a simple polymerase chain reaction (PCR)-based assay. In other cases, however, many dierent mutations may underlie a disorder (allelic heterogeneity). Depending on the size of the gene(s), this may render molecular diagnosis very costly and time-consuming. In addition, molecular diagnosis may be further complicated by the fact that mutations in a number of dierent genes may cause similar or indistinguishable phenotypes (genetic heterogeneity).
Despite the fact that today only a small percentage of neurogenetic disorders can be treated eciently, molecular diagnosis is increasingly important, because it may provide valuable information for the aected individuals and their families in order to make informed choices on life and family planning.
These guidelines are designed to provide practical help for the clinical neurologist to make appropriate use of the possibilities of molecular diagnosis of neurologic disorders in Europe. Genetic classi®cation of disorders follows, if applicable, the most comprehensive catalogue of human hereditary diseases, the`Online Mendelian Inheritance in Man (MIM)' (http:// www.ncbi.nlm.nih.gov.omim), which is maintained by the National Center of Biotechnology Information (NCBI).`MIM-numbers' are given in the text and in the Table 1 for easy reference.
General principles of molecular diagnosis
The primary goal of molecular diagnosis is to provide help for the individual patient, client and/or their families. Reducing the prevalence of inherited disorders in a population or in subsequent generations may be a secondary eect, but must never be allowed to guide the process of genetic counselling.
Genetic counselling
It must always be kept in mind that the molecular genetic diagnosis of an inherited disorder aects not only the patient, but also the entire family. Therefore, genetic counselling is an essential component of diagnosis of inherited disorders. Sensitive and informed counselling provides patients and families a foundation for decisions about testing. Patients should be counselled as to the clinical features and course of the respective disease as well as to potential consequences for the family, taking into consideration the most important genetic parameters such as mode of inheritance and penetrance. If the treating neurologist does not have thorough experience with inherited disorders, counselling by an experienced counsellor from a department of human genetics or another genetic counselling unit is strongly advised. In most situations, genetic testing should not be performed until adequate counselling has been provided.
In the case of predictive testing (see below), psychological counselling by appropriately trained persons is essential and mandatory before testing and after results have been disclosed.
Informed consent
As is true for all diagnostic procedures, the essential prerequisite for molecular diagnosis is the informed and voluntary consent of the patient. Therefore, the neurologist should establish that a patient or lawful surrogate is capable of comprehending relevant information and capable of exercising informed choices. Molecular genetic diagnostic tests should not be performed at the request of members of the patients' families or other third parties (e.g. insurers, employers) without the express written consent of the patient.
Con®dentiality
Test results suggesting that patients or family members carry mutations that indicate or predict a major neurologic disorder or a susceptibility to a neurologic disorder are highly sensitive. Therefore, rigorous measures to ensure con®dentiality should be taken. Test results should never be disclosed to a third party without explicit written consent from the patient or their lawful surrogates.
Pre-symptomatic diagnosis
The identi®cation of disease genes allows presymptomatic (predictive) diagnosis in many cases. Guidelines for pre-symptomatic diagnosis have been issued by the International Huntington's Disease Society and the World Federation of Neurology for Huntington's disease (International Huntington Association and the World Federation of Neurology Research Group on Huntington's Chorea, 1994). These guidelines which include extensive pre-and post-test counselling and thorough psychological support during the extensive process should be followed in all cases of pre-symptomatic diagnosis. Generally, pre-symptomatic diagnosis should be provided within the setting of a department of Human Genetics. If no clear therapeutic consequences can be envisioned, pre-symptomatic diagnosis should not be performed in minors. 
Indirect' molecular diagnosis
Knowledge of the chromosomal position of a disease gene allows molecular support for the diagnosis, even if the disease gene itself is unknown or if analysis is unfeasible.`Indirect' molecular diagnosis is limited to risk determination for an individual in whose family an inherited neurologic disease has already been diagnosed clinically. The method is based on the analysis of DNA markers known to be closely linked to the disease under investigation. Determination of these marker alleles in healthy and aected family members allows the identi®cation of the disease-gene bearing chromosome in this particular family. It must be emphasized that accurate clinical diagnosis in at least one aected family member is an absolute prerequisite for this type of molecular diagnosis and there is a small but de®nite error rate with this sort of linkage analysis. Until the gene for Huntington's disease was identi®ed in 1993, predictive testing for HD was the most widely used application for indirect molecular diagnosis. As more and more disease genes are identi®ed, direct mutational analysis becomes increasingly important.
Practical approach to molecular diagnosis
The patient con®rms his informed consent to the procedure in writing (see form attached). Usually, 10±20 ml of whole blood (EDTA) are sucient. The blood can be mailed without freezing or refrigeration. Delay of 3 to 5 days before DNA extraction is acceptable. It is crucial, that the tubes are clearly labelled, and that the clinical information including family history and the informed consent are contained within the shipment. Section II of these guidelines contains a summary of the possibilities and limitations of molecular genetic diagnosis of some important inherited neurologic diseases. Practical issues, such as diagnostic criteria that help to decide whether a molecular diagnostic should be ordered, are emphasized, and basic aspects are covered only as needed. References are limited to recent reviews and some key articles. This section will appear in two parts in this and the next issue of the European Journal of Neurology. A Table 2 at the end of section II will oer a more comprehensive listing of neurogenetic disorders, which are dealt within the respective issue, with information on the types of mutation and the availability of molecular diagnosis. This listing will not be complete, but attempts to be helpful in most clinical cases. Original papers on gene mapping and cloning are referenced here.
From a practical point of view, the availability of molecular diagnosis for a particular disorder will be classi®ed as follows: A: Routine diagnosis: The institution is able to provide a molecular diagnosis generally within 4 weeks. This applies particularly to diseases which are caused by expansions of repetitive trinucleotide sequences or other speci®c mutations. B: Molecular diagnosis is a routine procedure but limited by the complexity of the disorder. This usually applies to diseases which may be caused by a number of dierent point mutations within a gene, requiring sequencing of a number of exons. Because of the large number of disorders covered, this section of the guidelines will be published in this and the next issue of the European Journal of Neurology. In the current issue, non-degenerative movement disorders, inherited ataxias, neurodegenerative disorders, dementias and myopathies and muscular atrophies will be covered. The upcoming issue will deal with skeletal muscle channelopathies, neuropathies, epilepsies, neurovascular disorders, neurocutanous syndromes and mitochondrial diseases.
Molecular diagnosis of non-degenerative movement disorders Thomas Gasser, Huw Morris, Tim Lynch
The clinically and etiologically heterogeneous syndromes of non-degenerative movement disorders, that have traditionally been classi®ed phenomenologically according to the predominant abnormal movement are now being reclassi®ed on the basis of the underlying molecular defect. Because of this marked heterogeneity, however, molecular diagnosis is practically available only in a relatively small proportion of cases.
The primary dystonias
Primary dystonias are characterized by involuntary muscle contractions leading to twisting and repetitive movements with no discernible structural or metabolic cause. A number of distinct genetic forms have been identi®ed, but only in some instances, molecular diagnosis is routinely available (Muller et al., 1998) .
Generalized torsion dystonia (MIM 128 000)
A deletion of the trinucleotide GAG (encoding glutamic acid) in the gene for torsin A on chromosome 9q34 has been identi®ed in patients with autosomal-dominantly inherited early onset generalized dystonia (DYT1) (Ozelius et al., 1997) . The vast majority of patients with this mutation have dystonia beginning in the ®rst or second decade, usually in an extremity, and progressing relatively rapidly to a generalized form. Approximately 50% of patients with this phenotype will carry a mutation, and molecular diagnosis is warranted and easily available in this group. In some instances, the mutations can also be found in patients with early onset (<25 years) focal, segmental and multifocal dystonias with onset in an extremity, but occurs extremely rarely, if at all, in patients with typical adult-onset cervical or cranial dystonia. Important causes of secondary dystonia (perinatal hypoxia, Wilson's disease) should have been excluded. The reduced penetrance of about 30% has to be taken into account during the counselling process. This also means that a positive family history is supportive, but not a necessary prerequisite to consider DYT1-dystonia (Bressman et al., 2000) .
Other variants of dystonia
A rarer variant of dominant primary dystonia, doparesponsive dystonia (MIM 128 230) is caused by pointmutations in the gene for GTP-cyclohydrolase I in the 302 T. Gasser et al. majority of cases (Furukawa and Kish, 1999) . Again, the phenotype is usually characterized by a childhood onset of dystonia, aecting the extremities ®rst, but rarely, craniocervical dystonia may be the only manifestation. As a large number of dierent mutations have been described that are scattered over the entire gene (and could not even be detected in all cases within the coding region), the practical role of molecular diagnosis is limited. Fortunately, a suspicion of dopa-responsive dystonia can usually be con®rmed by the excellent response to L-dopa treatment, so that molecular analysis is frequently not necessary.
In other forms of dystonia, such as the myoclonus± dystonia syndrome (MDS, MIM 159 900), or`rapidonset dystonia-parkinsonism' (MIM 128 235), which are listed in the Table 3 , genes have been mapped but not cloned, and molecular diagnosis is not available.
Other movement disorders
Sequence analysis of the ATP7B gene causing Wilson's disease (MIM 277 900) is possible in individual patients. Approximately 55% of cases in a Caucasian population harbour mutations exons 7, 8, 14, 15, or 18. The other mutations are scattered more or less evenly across the rest of the gene. Identi®cation of a mutation in an index patient in a family allows pre-symptomatic testing in other at risk family members, which may be particularly important in this disease, because preventive and therapeutic measures can be taken. However in most cases, laboratory studies, particularly copper excretion in urine, is the diagnostic method of choice in Wilson's disease.
Although essential tremor (MIM 190 300) is the most prevalent movement disorder and autosomal dominant inheritance is common, only two genetic loci have been mapped, but no gene has been cloned so far. No locus is known for the restless legs-syndrome (MIM 102 300), another common movement disorder with frequent autosomal dominant inheritance. Problems of genetic heterogeneity or uncertainties in de®ning the clinical phenotype may be responsible.
Movement disorders in the setting of neurodegeneration (such as Huntington's disease, Parkinson's disease) are dealt with in the section on Neurodegenerative disorders.
Molecular diagnosis of inherited ataxias Nicholas Wood
There has been rapid progress in our understanding of the molecular basis of the inherited ataxias (Klockgether and Dichgans, 1997) . Although as single entities these disorders are rare, cumulatively they represent a major health burden. Moreover, the question often arises as to the role of the currently identi®ed genes in idiopathic/ sporadic ataxias.
This section is divided into two main parts the autosomal recessive and autosomal dominant ataxias. X-linked inheritance is exceedingly rare and the clinical picture is usually predominated by other features.
Autosomal recessive ataxias
Friedreich's ataxia (FA, MIM 229 300) is the most common of the autosomal recessive ataxias and accounts for at least 50% of the cases of hereditary ataxia in most large series reported from Europe and the United States. The prevalence of the disease in these regions is similar, between 1 and 2 per 100 000. The disease usually starts in the ®rst or second decade, is relentlessly progressive and is characterized by additional features including pyramidal signs, large ®bre neuropathy, skeletal abnormalities (pes cavus and scoliosis), cardiomyopathy, and more rarely optic atrophy, deafness and diabetes. Cases considered atypical for Friedreich's ataxia (e.g. with onset after age 25 or with retained re¯exes) have now been recognized as manifestations of Frataxin gene mutations.
The gene for Friedreich's ataxia is located on chromosome 9q13. The predominant mutation is a trinucleotide repeat (GAA) in intron 1 of this gene. Expansion of both alleles was found in most patients. In a minority of patients point mutations are found on one allele and an expansion on the other. This is the ®rst autosomal recessive condition found to be the result of a dynamic repeat. On normal chromosomes the number of GAA repeats varies from 7 to 22 units, whereas on disease chromosomes, the range is anything from around 100±2000 repeats.
The rarity of point mutations means that it is extremely improbable that a case of FA will have two point mutations and therefore a normal sized repeat length on both chromosomes argues strongly against a diagnosis of Friedreich's ataxia. Some laboratories oer sequencing of the frataxin gene as a service to complement the GAA repeat testing. It should be noted that one of the most frequent requests to a DNA lab is to test for carrier status in the partner of a Friedreich's patient. It should be emphasized to the partner that the test (i.e. the GAA repeat) is not perfect as the assay will not detect point mutations. If no abnormal repeat is detected the chance of an aected ospring is less than 1 : 10 000.
Other autosomal recessive ataxias
There is a long list of other inherited ataxic syndromes, most of which remain to be elucidated on the molecular Guidelines for the molecular diagnosis LGMDH2H AR Autosomal dominant ataxias (ADCA)
The autosomal dominant ataxias (ADCAs) are a clinically and genetically complex group of neurodegenerative disorders. ADCA type I is characterized by a progressive cerebellar ataxia, variably associated with other neurological features such as ophthalmoplegia, optic atrophy, peripheral neuropathy, pyramidal and extrapyramidal signs. The presence and severity of these signs is, in part, dependent on the duration of the disease. Mild or moderate dementia may occur but it is usually not a prominent early feature. ADCA type II is clinically distinguished from the ADCA type I by the presence of pigmentary macular dystrophy, whereas ADCA type III is a relatively`pure' cerebellar syndrome and generally starts at a later age. This clinical classi®cation is still useful, despite the tremendous improvements in our understanding of the genetic basis, because it provides a framework which can be used in the clinic and helps direct the genetic evaluation. The nomenclature of the genes has been based on the term spinocerebellar ataxia (SCA). The SCAs are numbered in chronological order.
To date molecular diagnosis is routinely available for SCAs 1, 2, 3, 6, and 7. These disorders have a number of common features including onset in adult life (predominantly) and a progressive course. Additional features (see above) may vary both within and between families. At a molecular level, although the genes encode very dierent proteins, the mutation is basically same, namely an expanded trinucleotide repeat sequence of CAG (Brice, 1998 ). All so far described are the results of a relatively modest expansion within the coding region. Although the exact number of repeats on both the normal and the abnormal allele varies between the dierent diseases, the normal range of repeats is in the 20 s, whereas for the disease carrying allele it tends to be over 40. The codon CAG encodes the amino acid glutamine and therefore all these disorders have an expanded polyglutamine tract within the relevant protein. The exact pathogenic mechanism remains unknown.
The assays are PCR based and relatively simple and quick to perform. With only some exceptions it is unusual to ®nd a positive SCA result in a sporadic case but if clinically suspected then it is still reasonable to include SCA testing in such patients. Note: This compilation of inherited neurologic disorders is not complete. The selection of the listed diseases was chosen relatively subjectively, its purpose is to give the reader an orientation point. The speed in which progress is made in molecular genetic research however, causes such tables to become outdated very quickly. In case of doubt it is recommended that current publications or special centres be consulted. For many if not for most of the diseases listed here, mutations in other currently unknown genes may also be responsible. Abbreviations: AD autosomal dominant; AR autosomal recessive; X X-chromosomal; mat maternal (mitochondrial) transmission; Pm Point mutation; Del Deletion; Ins Insertion;
Trinuc Trinucleotid-repeat expansion. Availability of molecular diagnosis: A: Routine procedure, commercially available, results usually within 4 weeks; B: Routine procedure, but may be time-consuming and expensive, usually as the result of occurrence of multiple mutations; results may take several months; C: Usually available only within research setting; D: Not yet available.
Recently SCA 8 has been reported to be caused by a much larger repeat sequence which is not translated into protein (i.e. dierent from the other SCAs). It still remains to be established if this repeat is de®nitely pathogenic, as expansions have been found in several asymptomatic individuals.
The rare autosomal dominant periodic (episodic) ataxias are ion channel disorders and require sequencing of the entire gene(s) to identify the mutations. As the genes for ion channels are usually very large, routine sequencing is prohibitively expensive. However, sequencing may be done by research groups who are interested in these disorders (see chapter by Jurkat-Rott and Lehmann-Horn on Molecular diagnosis of channelopathies).
Molecular diagnosis of neurodegenerative disorders Thomas Gasser, Huw Morris, Tim Lynch Huntington's disease
Huntington's disease (HD, MIM 143 100) is the`prototypic' neurogenetic disorder. It is usually characterized by the triad of a choreic movement disorder, cognitive decline and personality changes. Clinical manifestations may be highly variable, however, and particularly in juvenile cases, akinesia, rigidity, or epileptic seizures may occur. The disease is caused by the expansion of a CAG-triplet in the ®rst exon of the gene for huntington, leading to the formation of an elongated polyglutamine domain within the protein (Huntington's Disease Collaborative Research Group, 1993; Brice, 1998) (analogous to the SCAs). Molecular diagnosis is technically simple, as with other trinucleotide repeat diseases.
The indications and consequences of diagnostic and pre-symptomatic molecular diagnosis have been studied widely in HD. Based on these experiences, guidelines have been developed, that should be followed, in adapted form, also in the genetic diagnosis of other neurologic disorders (The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group, 1998). In particular, a thorough counselling process must ensure that only patients and families who can deal appropriately with their knowledge are selected. This is of course particularly relevant for pre-symptomatic testing.
As in other disorders caused by trinucleotide repeat expansions, onset of age and severity of the disease is inversely correlated to the size of the expansion. In suspected HD-cases with early onset it must be remembered, that parents may carry smaller size repeat expansions and may manifest the disease after their ospring. Molecular diagnosis in a child may therefore result in inadvertent pre-symptomatic testing in a parent (Scheidtmann et al., 1997 ).
Parkinson's disease
Until recently, the role of genetic factors in the etiology of Parkinson's disease (PD), has not been widely recognized. Today we know that mutations in several genes are able to cause monogenically inherited forms of Parkinson's disease (Gasser, 1999) . The discovery that mutations in the gene for a-synuclein can cause an early onset form of PD (MIM 168 601) is particularly interesting in the light of the fact that the a-synuclein protein is one of the major components of the histopathologic hallmark of PD, the Lewy body. Mutations in this gene are exceedingly rare, so that sequencing is not routinely warranted, except in early onset cases with a clear dominant family history.
Mutations in the parkin gene on chromosome 6, which have been found in patients with an autosomal± recessive syndrome of juvenile parkinsonism appear to be causative in a substantial portion of patients with L-dopa responsive parkinsonism and juvenile onset of the disease. Mutations can be found in up to 75% of those with disease onset under 20, and still about 5% with onset under 40 (LuÈ cking et al., 2000) . Genetic diagnosis may be technically dicult, as point mutations as well as homozygous and heterozygous exon deletions have been described, necessitating full sequence analysis as well as gene dosage studies. Other genes or loci associated with PD still have no role in molecular diagnosis.
Amyotrophic lateral sclerosis
Less than 10% of cases with ALS (MIM 105 400) show dominant inheritance, and only about 20% of those are caused by mutations in the gene for superoxide dismutase 1 (SOD1, MIM 147 450) on chromosome 21. Despite the low prevalence of these mutations, sequencing of the relatively small SOD1-gene should be considered in patients from families with clear dominant inheritance, in order to be able to oer presymptomatic or pre-natal diagnosis, if this is wanted by family members.
Familial spastic paraplegias
The familial spastic paraplegias are a heterogeneous group of neurodegenerative disorders that are characterized by a slowly progressive pyramidal tract dysfunction, which occurs in some cases in isolation, in Guidelines for the molecular diagnosis other cases in association with a variety of other neurologic signs and symptoms (Reid, 1999) . As in the cerebellar ataxias, classi®cations based on these additional symptoms have not been very helpful, and are now being replaced by a genetic classi®cation. To date, eight genetically distinct forms are recognized, and it is clear that there are still families that are unlinked to any of these loci. Three of the genes have been identi®ed.
Mutations in the proteolipid protein (PLP) gene on the X-chromosome are associated with a wide variety of phenotypes, ranging from severe, infantile forms of Pelizaeus±Merzbacher disease (PMD, MIM 260 600) to relatively mild pure spastic paraplegia of adult onset.
Pelizaeus±Merzbacher disease (PMD) typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment. Neurologic de®-cits progress to include severe spasticity and ataxia and death often occurs in childhood. Other mutations in the same gene, however, may manifest as a relatively pure spastic paraparesis (SPG2, MIM 312 920) with usually a normal lifespan. Female carriers may show mild to moderate signs of the disease. Still other mutations may lead to`complicated' spastic paraparesis, often including autonomic dysfunction (such as spastic bladder disturbance), ataxia, and nystagmus. A clear distinction cannot be drawn on objective criteria between complicated spastic paraplegia and relatively mild PMD (such as the`PLP null syndrome').
Clinical diagnosis depends on the typical neurologic ®ndings and disease progression, X-linked inheritance pattern, and abnormal myelination on MRI (in cases with CNS involvement). Molecular diagnosis by sequence analysis is oered by many laboratories.
A rare form of adult onset of pure spastic paraplegia with recessive inheritance (SPG7, MIM 602 783) was found to be caused by a gene on chromosome 16 called paraplegin. Interestingly, the encoded protein is highly homologous to the yeast mitochondrial ATPases, which have both proteolytic and chaperon-like activities at the inner mitochondrial membrane. Immuno¯uorescence analysis and import experiments showed that paraplegin localizes to mitochondria. Analysis of muscle biopsies from two patients carrying paraplegin mutations showed typical signs of mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration in HSP-type disorders. This appears to be a rare cause of spastic paraplegia and molecular diagnosis is not oered at this time.
The gene underlying the most common form of spastic paraplegia, the one linked to chromosome 14, has recently been identi®ed (SPG4, spastin, MIM 604 277). It accounts for approximately 50% of all cases with a pure SPG-phenotype, adult-onset, and a family history compatible with autosomal dominant inheritance. Again, complete sequencing of this relatively large gene is necessary, but justi®able, in suspected cases as a result of the high prevalence of this disorder.
Molecular diagnosis of inherited dementias M. Rossor
The majority of inherited degenerative dementias occurs as autosomal dominant disorders with similar phenotypes to sporadic disease. The frequency of familial occurrence varies from being a rarity (e.g. in dementia with Lewy bodies) to relatively frequent, as with the frontotemporal lobe degenerations. A number of pathogenic mutations associated with familial degenerative dementias have now been identi®ed providing opportunities for speci®c diagnoses in aected patients and pre-symptomatic testing in at risk individuals.
It is particularly important in dementing disorders to ensure adequate genetic counselling prior to any attempt at molecular genetic diagnosis and to obtain consent from the patient and/or family carer (Post et al., 1997) . It should also be pointed out that a post mortem diagnosis of the cause of a familial degenerative dementia can provide critically important information in the future counselling for the family and should be discussed.
Alzheimer's disease
Alzheimer's disease is the most common type of the primary degenerative dementia. Mutations in three genes have been found to be associated with a form of the disease that is inherited in an autosomal dominant fashion with high penetrance. Overall, less than 5% of all cases can be accounted for by mutations in these genes. Amongst them, mutations in the gene for presenilin 1 (PS1, MIM 104 311) on chromosome 14 is most common, whereas mutations in the gene for presenilin 2 (PS2, MIM 600 759, chromosome 1) and amyloid precursor protein (APP, MIM 104 760, chromosome 21) are exceedingly rare (Mayeux and Ottman, 1998 ). An early onset (in the 40s and 50s) is common to all these monogenic forms, and along with a clearly positive family history, should act as an indication for molecular genetic diagnosis. Mutational screening in individuals without a family history is rarely indicated unless there is a very characteristic phenotype and inadequate pedigree history.
In addition to the mutations mentioned above, which can cause AD with high penetrance, an expanding list of genetic risk factors is being identi®ed for dementias of which the apolipoprotein E4 allele as a risk factor for AD is the best established. However, as the E4 allele is neither necessary nor sucient to cause AD, there is a wide consensus that at present there is no clear bene®t in apolipoprotein E genotyping to assist with diagnosis (McKeith and Morris, 1996) nor with pre-symptomatic risk assessment. Other risk factors, such as the a2-macroglobulin and the interleukin-6 gene are suspected, but their role is less well established. It is conceivable, however, that response to certain forms of treatment will be found to vary, according to the combination of genetic susceptibilities in a given individual, so that their knowledge may be of clinical importance in the future.
Other degenerative dementias
A group of familial disorders characterized by a predominantly frontotemporal distribution of cortical cerebral atrophy and a clinical picture of prominent behavioural changes and dementia, variably associated with a variety of other neurologic de®cits, such as parkinsonism or motoneuron degeneration has recently come into focus. These cases have in common a pathologic deposition of the microtubule associated protein tau (MAPTau). Historically, at least a subset of these patients had been subsumed under the heading of Pick's disease. The currently accepted terminology for the inherited forms is that of frontotemporal dementia with parkinsonism linked to chromosome 17 (Foster et al., 1997) . Mutations in the gene for MAPtau on chromosome 17 have been identi®ed in a number of families with several dierent clinical presentations, such as`classic' frontotemporal dementia, familial subcortical gliosis, corticobasal degeneration and even progressive supranuclear palsy. The prevalence of taumutations in a population of sporadic patients with the phenotype of frontotemporal degeneration from a dementia clinic however, is well below 10%, so that molecular diagnosis should be restricted to those cases with a clear family history.
Prion diseases (spongiform encephalopathies, in humans usually as Creutzfeldt-Jakob disease, CJD, MIM 123 400) may occur in idiopathic, acquired, or inherited disorders. A clearly positive family history is found in 10±20% of cases. Numerous dierent mutations in the prion protein gene have been identi®ed in hereditary cases. Complete sequencing of the prion protein gene is provided by several centres and should be oered, given the appropriate counselling, in all cases with a strong clinical suspicion of CJD.
Other degenerative disorders associated with dementia
Many familial disorders may be associated with cognitive impairment which is overshadowed by other clinical features and many metabolic disorders with recessive inheritance. These may present to adult neurologists (Coker, 1991) , are not discussed further here. Mutations in the synuclein, superoxide dismutase, huntingtin, and ataxin genes occur in familial neurological disorders in which cognitive disturbance may also occur (see also chapters on Inherited degenerative movement disorders and Inherited ataxias).
Dementia, along with recurrent ischemic events, is also a major feature of`cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy' (CADASIL, MIM 125 310), which is caused by mutations in the Notch 3 gene (see also chapter on Neurovascular disorders). (Zerres et al., 1997; Biros and Forrest, 1999) .
All three forms are caused by mutations in a single gene. In 95±98% of cases, a homozygous deletion of exon 7 of the telomeric copy of the survival motor neurone gene (SMN1), which maps to chromosome 5q13, can be demonstrated by PCR. In the remaining 2±5% of cases the disease is caused by point mutations or small deletions or insertions in this gene. Most of these cases are compound heterozygotes with the common SMN1 deletion on one chromosome and another mutation on its homologue. The role of the gene product, the SMN protein, which is present in motoneurons and in other tissues is not yet clear. It is most probably that it is involved in RNA metabolism.
The risk for parents who already have had a child with SMA to have another aected child is 1 in 4. The risk for heterozygous healthy siblings of an SMA patient of having an aected child is 2/31 /50´ 1/300, and the risk for having an aected child for mildly aected or non-manifesting individuals with a homozygous mutation of the SMN1 gene is 1/100 (assuming a frequency of heterozygotes in the general population of 1/50).
Genetic testing including pre-natal diagnosis should be oered to all couples having a genetic risk of , but should also be available to those of the 1/100±1/300 risk group. An important prerequisite, however, is the previous identi®cation of the mutation(s) in an aected individual from the family. If the proband is already deceased, which is common in SMA, the clinician should bear in mind that DNA can also be obtained from biological material such as samples of organs kept in formalin or in paran blocks, dried drops of blood on blotting paper (obtained during new born screening for PKU), dried fragments of umbilical cords or milkteeth sometimes in the possession of parents.
Even if the diagnosis in the index patient cannot be con®rmed molecularly, the demonstrated absence of a homozygous deletion in a proband can reduce the recurrence risk of SMA from 25 to 2%.
Inherited disorders with predominant involvement of skeletal muscle Duchenne/Becker muscular dystrophy (DMD/BMD, MIM 310 200) Duchenne/Becker muscular dystrophy is an X-linked recessive condition. The frequency of DMD is 1 in 3000 and BMD 1 in 20.000. The onset of DMD in most of the cases is below 5 years. Characteristic traits of the clinical picture are progressive muscular weakness ± mainly proximal, calf pseudohypertrophy, features of myopathy in muscle biopsy and in EMG as well as markedly elevated serum creatine kinase. In BMD the onset is later and the course of the disease is generally milder, but there is a remarkable variability of clinical expression.
Immunohistochemistry of the muscle biopsies shows absence of dystrophin in DMD and markedly reduced dystrophin in BMD.
The huge dystrophin gene, which spans 2.4 Mb of DNA, maps to chromosome Xp21 and includes 79 exons. DMD and BMD are caused by mutations in the dystrophin gene. Deletions of a variable number of exons are the most common mutation in approximately 60% of cases, duplications are found in 5±10%. Point mutations are responsible in the remainder.
The molecular diagnosis of DMD/BMD can be done from blood DNA or by examining the gene product, dystrophin, in a muscle biopsy. DNA analysis detects deletions and most duplications. Because of enormous size of the gene, point mutations are dicult to detect. If a PCR-based assay for deletions is negative, it is often worthwhile to perform dystrophin analysis based on immunohistochemistry and on western blot (immunoblot). If dystrophin analysis con®rms the diagnosis of DMD/BMD, detection of asymptomatic carriers of the mutated gene or pre-natal diagnosis can be carried out by genetic linkage analysis even if no mutation can be detected (see chapter on indirect DNA-testing in Section I).
Pre-natal diagnosis is oered not only to the con®rmed carriers but also to women who previously gave birth to aected boys (isolated cases) and DNA analysis has shown that they are not the carriers, as there is a high probability of gonadal mosaicism. For review, see Kissel and Mendell, 1999. Facioscapulohumeral muscular dystrophy (FSHD, MIM 158 900) Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant condition. The frequency is 1 : 20.000. Distribution of muscle weakness and wasting reveals descending progression involving the face, shoulder girdle, hip girdle and peroneal muscles (Kissel, 1999) .
The gene for FSHD is located on chromosome 4q35. Molecular diagnosis in FSHD is complicated by the fact that the gene itself and the precise nature of the mutation is still not known. It is known, however, that in normal controls, southern blots of DNA digested with EcoRI reveal a large fragment of over 30 kb, whereas in most FSHD patients, the respective fragment is smaller (between 12 and 30 kb). This is probably because of a deletion of variable size in a 3.3-kb repetitive sequence (D 4 Z 4 ). Interpretation of molecular studies in FSHD is not straightforward, because 30% of the subjects with the deletion are asymptomatic. On the other hand, a deletion has been detected only in 95% of the patients aected with FSHD. There is also evidence for genetic heterogeneity in FSHD (linkage to another gene) and for the occurrence of germinal mosaicism: as many as 20% of the reported sporadic patients have a mosaic parent. Nevertheless, molecular testing is widely available and should be performed if there is a clinical suspicion of the disease.
Myotonic Dystrophy (DM, MIM 160 900) Myotonic dystrophy is one of the most frequent muscular dystrophies aecting adults and children (Thornton, 1999) .
Besides wasting and myotonia in skeletal muscles in a characteristic distribution (facial muscles, mostly temporal, masseter and sternocleidomastoid, as well as distal limb muscles) the disease also aects several other organ systems. Additional features are male baldness, cataract, cognitive changes, hormonal disturbances, cardiomyopathy, and visceral symptoms.
The genetic basis for DM is the expansion of a CTG repeat in the DMPK gene on 19q13. Normal alleles vary from 5 to 37 CTGs. The range 38±49 is considered as pre-mutation; expansion over 50 CTGs is usually associated with clinical symptoms. As in other diseases with repeat expansions, molecular diagnosis is easily done with a PCR-based assay or southern blot.
Another autosomal dominant disorder that closely resembles DM except that muscle weakness is predominantly proximal and less pronounced whilst hypertrophy of calves is frequent, has been described under the name of proximal myotonic myopathy (PROMM, MIM 600 109).
Congenital myopathies
This is a large group of diseases steadily increasing as a result of development of research techniques and diagnostic methods. The common clinical denominators for the whole group are: congenital¯oppiness, muscle weakness, slimness, frequent skeletal dysmorphism.
The diagnosis is based on morphological abnormalities speci®c for each myopathy. These conditions are usually stationary or slowly progressive. Of the large group of congenital myopathies, only a few will be discussed.
Central core disease (CCD) is transmitted as an autosomal dominant trait (MIM 117 000). The characteristic feature of muscle histopathology is an amorphous area in the centre of the ®bre. CCD is caused by mutations in the rhyanodine receptor on chromosome 19q13, and is allelic (dierent mutations in a single gene) to one form of malignant hyperthermia susceptibility (MHS, MIM 145 600). Patients with CCD are at risk for malignant hyperthermia and both conditions may appear in the same family. MHS is genetically heterogeneous. It has been estimated that approximately 50% of the cases are the result of mutations in the rhyanodine receptor, but four other loci have been identi®ed. Identi®cation of a particular mutation in a family with an individual known to be susceptible to malignant hyperthermia may be helpful to counsel family members and may obviate a muscle biopsy to rule out the disorder in family members.
The characteristic histopathological feature for nemaline myopathy (MIM 161 800) is the presence of small rods, originating from the Z-band of the muscle ®bre, staining red by the Gomori technique. The disease is transmitted as an autosomal recessive (maps to 2q21.2±2q22) or autosomal dominant trait (maps to 1q 21±23). The gene product is a-tropomyosine. The course of the disease is very variable. Three forms of the disease are recognized: neonatal (very severe, usually lethal), childhood and adult ones.
In myotubular or centronuclear myopathy (MIM 310 400) the nuclei are situated centrally, surrounded by a pale halo. The muscle ®bers show signs of immaturity. There are several dierent forms of myotubular myopathy, transmitted in an X-linked fashion (mapped to Xq28), as well as in an autosomal recessive and autosomal dominant form.
Emery-Dreifuss type muscular dystrophy (MIM 310 300) The clinical features are: joint contractures mostly in elbows, knees, ankles, neck; moderate weakness and wasting of muscles, mostly of a proximal distribution in the upper extremities and a distal pattern in the legs; cardiac symptoms also occur. The ®rst symptoms start usually in childhood as contractures. Cardiac symptoms may occur, also in otherwise asymptomatic heterozygous female carriers.
The disease is genetically heterogeneous ± the main mode of transmission is X-linked. In these cases, deletions are found in a small gene on Xq28 (Emerin). Most mutations are private, i.e. dierent in each aected family. Therefore complete sequencing is usually necessary.
Another type of ED is transmitted as an autosomal dominant. The gene has been localized to chromosome 1, and identi®ed as lamin A/C.
Limb-girdle muscular dystrophies
The limb±girdle muscular dystrophies (LGMDs) are a group of genetically determined disorders with the common feature of a progressive proximal muscle weakness. As a result of genetic heterogeneity and clinical similarity the precise LGMD diagnosis is one of the most dicult to make. Eight autosomal recessive LGMD variants are known. Four of them (sarcoglycanopathies, SGPs) result from mutations in the genes coding for dystrophin associated proteins, sarcoglycans (SG) a, b, c, d. In SGPs cardiac involvement is possible. The subset of autosomal recessive LGMD without SG involvement is represented by four variants. One of them is caused by mutations in the calpain 3 (CANP3) gene, another variant results from mutations in the dysferlin (DYSF) gene. The genes for the remaining two forms have not yet been identi®ed. 5±10% of LGMDs are inherited in an autosomal dominant fashion. At present six loci have been mapped. Of these only the gene encoding caveolin-3 (CAV3) has been identi®ed so far. Cardiac involvement has been reported in two dominant LGMD phenotypes.
The diagnosis of autosomal recessive LGMD is usually accomplished by immunohistochemistry using of speci®c antibodies recognizing SG complex in muscle tissue. The mutation in any gene encoding one of the SGs would result in a primary de®ciency of this particular SG and a secondary de®ciency in the remaining ones. This approach allows to identify sarcoglycanopathies.
If SGs appear normal, the use of antibodies recognizing CANP3 and DYSF in muscles is recommended. De®ciency of theses proteins indicate dystrophy subtype and permit direct mutations search at particular LGMD genes.
X-linked bulbospinal muscular atrophy, Kennedy disease (MIM 313 200) X-SBMA is an X-linked recessive, slowly progressive disorder of adult onset caused by the loss of lower motoneurons. Muscle wasting is accompanied by a variable degree of gynecomastia and reduced fertility. The mutation is the expansion of a CAG repeat in the ®rst exon of the androgen receptor (AR) gene (abnormal range over 35 repeats; normal alleles ± 9±34 repeats). This disorder may be an important dierential diagnosis to ALS or adult forms of SMA. Molecular analysis is based on PCR ampli®cation of the CAG repeat region and routinely available.
